-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $150

Benzinga·10/05/2026 19:25:02
Diffusion vocale
Citigroup analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $150.